Follow-up of IgD-κ multiple myeloma by monitoring free light chains and total heavy chain IgD: A case report

ELENA DE SANTIS¹, SERENA MASI¹, IOLE CORDONE¹, FRANCESCO PISANI², CECILIA ZUPPI³, FABRIZIO MATTEI⁴, LAURA CONTI¹ and GIOVANNA CIGLIANA¹

¹Clinical Pathology Unit; ²Hematology and Stem Cell Transplantation Unit, Italian National Cancer Institute ‘Regina Elena’, I-00144 Rome; ³Department of Laboratory Medicine and Diagnostics, University Hospital Agostino Gemelli, I-00168 Rome; ⁴Department of Hematology, Oncology and Molecular Medicine, National Institute of Health, I-00161 Rome, Italy

Received December 3, 2015; Accepted June 27, 2016

DO: 10.3892/ol.2016.4869

Abstract. Immunoglobulin (Ig)D-κ multiple myeloma (MM) is a rare neoplastic disease characterized by an aggressive and rapidly progressing course, which constitutes only a very small proportion of all MM cases. In the present report, the clinical case of a 51-year-old Caucasian woman diagnosed with IgD-κ MM is described. The patient underwent different chemotherapeutic treatments subsequently to a single autologous stem cell transplantation. Despite the inherent difficulty of monitoring IgD levels and performing serum immunofixation electrophoresis, the clinical outcome of the patient was almost uniquely monitored by measuring the levels of κ and λ free light chains (FLCs) and total heavy chain IgD. The data suggest the non-invasive potential and usefulness of FLCs evaluation for early detection of stringent complete remission, follow-up and early detection of disease relapse. In addition, this diagnostic procedure has successfully been employed for the therapeutic monitoring of the present patient, and may represent a very helpful, non-invasive tool for the follow-up of IgD myeloma patients without the requirement of serial bone marrow aspirate.

Introduction

Multiple myeloma (MM) is a plasma cell (PC) disorder that induces anemia, skeletal destruction, renal failure and hypercalcemia (1). It is the second most common hematological malignancy, and it is characterized by the presence of a monoclonal immunoglobulin (Ig) expressed and secreted in the bone marrow, where there is a collection of abnormal PCs that interfere with the production of normal blood cells (2).

IgD MM constitutes ≤2% of all MM cases, displays generally an aggressive phenotype (often with renal failure) and is usually characterized by poor prognosis (3). IgD-κ occurs only in 3-4% of all IgD MM cases, and is also associated with the difficulty of obtaining a reliable diagnosis and of conducting a constant and precise follow-up (4).

The diagnostic panel for IgD-κ MM should include PC flow cytometry characterization, fluorescence in situ hybridization (FISH), serum protein electrophoresis (SPE), serum immunofixation electrophoresis (sIFE), measurement of serum free light chains (sFLCs) and total heavy chain IgD, and urinary IFE for Bence Jones (BJ) protein (5).

Diagnostically, with novel agent therapy (including thalidomide, bortezomib and lenalidomide) specifically integrated with autologous stem cells transplantation (ASCT) when feasible, the survival for IgD MM is improved; however, the outcomes remain inferior to those achieved in patients with other myeloma isotypes, thus highlighting the requirement for better and more innovative approaches in treatment and monitoring (6).

The present report describes the follow-up of a case of an IgD-K MM patient, who often refused to undergo a bone marrow aspirate, even in certain critical phases of the disease. Thus, given the occasional inability to obtain bone marrow aspirate samples, at times when a relapse was suspected, minimal residual disease (MRD) was alternatively monitored by serological evaluation of FLC and total heavy chain IgD levels (7,8).

The current report presents the case of a long survival patient monitored almost exclusively by sFLC and IgD measurements as an essential, non-invasive marker. Written informed consent was obtained from the patient [medical records no. 4249 on June 10, 2013 at Hematology and Stem Cell Trasplantation Unit, Italian National Cancer Institute ‘Regina Elena’ (Rome, Italy)].

Case report

In March 2007, a 51 year-old woman presented for the first time at the Hematology and Stem Cell Trasplantation Unit of the Italian National Cancer Institute ‘Regina Elena’ with...
DE SANTIS et al: IgD-κ MM FOLLOW-UP WITH FLCs AND TOTAL HEAVY CHAIN IgD MEASUREMENT

multiple osteolytic lesions. PC flow cytometry characterization (FACSCanto™; BD Biosciences, Franklin Lakes, NJ, USA) identified an infiltration (23% of bone marrow population) of cluster of differentiation (CD)38+CD138+CD28+CD56+CD117+CD19+CD45- tumor PCs, with κ-sFLC restriction, as illustrated by flow cytometric analysis at diagnosis (Fig. 1A). Bone marrow examination by FISH revealed no abnormalities.

sIFE and BJ protein IFE on urine evidenced the presence of an IgD-κ monoclonal component and κ light chains, respectively (Fig. 1B). In addition, sFLC quantification (The Binding Site Group, Ltd., Birmingham, UK) revealed a marked increase in κ-sFLC with an abnormal FLC κ/λ ratio (Table I). Total heavy chain IgD quantification (The Binding Site Group, Ltd.) confirmed the presence of elevated IgD levels (Fig. 1B and Table I).

The average and standard deviation values of β2-microglobulin (β2 M) levels were 7.47 and 3.77 mg/l, respectively (normal range 0.80-2.20 mg/l). Other classical serological parameters [calcium (Ca)-renal-anemia-bone criteria] were altered. The diagnosis was an IgD-κ MM stage IIIA.

According to the current clinical practice at the Italian National Cancer Institute ‘Regina Elena’, the patient underwent chemotherapy with two cycles of vincristine, doxorubicin (Adriblastina®) and dexamethasone (VAD regimen) from April until May 2007 (9). The patient was then treated with two cycles of cyclophosphamide (Endoxan Baxter®) from July until November 2007, and four subsequent cycles of bortezomib (Velcade®), Myocet® and dexamethasone (BMD regimen) from November 2007 until February 2008 (Fig. 2 and Table I). The FLC measurements and total IgD evalua-
tions commenced upon ASCT (10) and were extended until the relapse phase (Fig. 2). Following the first VAD cycle, bone marrow stem cells were collected.

The patient was classified as ‘non responder’ to the different chemotherapeutic agents; however, the patient was selected for ASCT in April 10, 2008 (Fig. 2). Following ASCT, severe complications occurred, including pneumonia with Morganella morganii infection and then sepsis. Based on these observations, the hematological asset of the patient was re-evaluated upon ASCT, and bone marrow immunophe-notyping revealed a 0.1% of PC population in the lymphocytes region. As displayed by post-ASCT flow cytometric analysis, the sFLC κ/λ ratio decreased, and no presence of neoplastic PCs was detected (Fig. 1A). In parallel, sIFE appeared without a monoclonal component, and the level of BJ protein was less pronounced overtime (Fig. 1B). Furthermore, these parameters were associated with a marked reduction in κ-sFLC (Fig. 3), suggesting that the patient was effectively responding to the treatment. However, osteolytic lesions were still present but did not progress overtime.
In November 2008, the patient was diagnosed with Guillain-Barré syndrome. Due to the several complications occurred during the course of this syndrome, the patient refused a second ASCT and other bone marrow aspirates. Therefore, the patient was regularly monitored with sFLC and total IgD measurements in order to assess the response to the

Table I. FLC/IgD values in the course of monitoring with BMD chemotherapy and ASCT.

| Therapy  | Therapy schedule | Date       | FLCs | Heavy chain total IgD |
|----------|------------------|------------|------|-----------------------|
|          |                  |            | \(k\) | \(\lambda\) | \(k/\lambda\) ratio |
| Pre-BMD  |                  | Oct 10 2007| 5,889.00 | 8.30 | 709.00 | 8,678.00 |
| BMD      | 1st cycle, basal | Oct 31 2007| 4,812.00 | 3.44 | 1,398.00 | ND |
|          | 1st cycle, 5 days| Nov 16 2007| 3,518.00 | 2.61 | 1,348.00 | ND |
|          | 2nd cycle, basal | Dec 12 2007| 3,352.00 | 2.82 | 1,188.00 | 5,028.00 |
|          | 2nd cycle, 5 days| Dec 14 2007| 2,539.00 | 2.09 | 1,215.00 | ND |
|          | 2nd cycle, 15 days| Dec 24 2007| 2,484.00 | 2.74 | 906.00 | 3,862.00 |
|          | 2nd cycle, 28 days| Jan 7 2008 | 3,432.00 | 2.93 | 1,171.00 | 4,966.00 |
|          | 3rd cycle, 5 days| Jan 11 2008| 2,651.00 | 2.26 | 1,173.00 | ND |
|          | 4th cycle, basal | Feb 4 2008 | 3,460.00 | 8.13 | 425.00 | 3,957.00 |
|          | 4th cycle, 7 days| Feb 11 2008| 2,627.00 | 8.00 | 328.00 | 4,050.00 |
|          | 4th cycle, 15 days| Feb 19 2008| 3,580.00 | 8.13 | 440.00 | 3,503.00 |
| Pre-ASCT |                  | Apr 10 2008| 5,149.00 | 8.00 | 643.00 | 8,406.00 |
| Post-ASCT| 15 days          | May 9 2008 | 42.09 | 14.10 | 2.91 | ND |
|          | 2 months         | Jul 23 2008| 19.92 | 71.40 | 0.28 | 6.44 |
|          | 4 months         | Sep 3 2008 | 27.41 | 59.32 | 0.46 | ND |
|          | 6 months         | Nov 3 2008 | 30.08 | 28.91 | 1.04 | 6.44 |
|          | 17 months        | Sep 17 2009| 25.83 | 17.77 | 1.45 | ND |
|          | 21 months        | Jan 20 2010| 24.26 | 26.43 | 0.92 | 8.65 |
|          | 24 months        | Apr 19 2010| 27.95 | 21.80 | 1.28 | ND |
|          | 43 months        | Feb 27 2012| 26.97 | 17.66 | 1.53 | 12.50 |
|          | 48 months\(^b\) | Jul 2 2012 | 37.02 | 16.62 | 2.23 | 208.00 |
|          | 56 months\(^b\) | Mar 6 2013 | 262.00 | 14.78 | 14.78 | 190.00 |
|          | 59 months\(^b\) | Jun 10 2013| 692.00 | 11.27 | 61.40 | 748.00 |

\(^{a}\)Values expressed in mg/l. Numbers in parentheses and inside the table represent the normal ranges. \(^{b}\)Relapse: BMD, bortezomib, Myocet\(^{®}\) and dexamethasone chemotherapy; ASCT, autologous stem cell transplant; ND, not determined; FLC, free light chain; Ig, immunoglobulin.
DE SANTIS et al.: IgD-κ MM FOLLOW-UP WITH FLCs AND TOTAL HEAVY CHAIN IgD MEASUREMENT

Figure 3. Graphical representation of serum free light chains, κ/λ ratio and IgD during the overall monitoring phase of the IgD-κ multiple myeloma patient. The plot depicts all collected data in the course of the monitoring of the patient, from October 2007 to June 2013. The numbers of cycles of bortezomib, Myocet® and dexamethasone chemotherapy are indicated. The black arrow represents the initiation of the relapse phase. ASCT, autologous stem cell transplant; BMD, bortezomib, Myocet® and dexamethasone chemotherapy; Ig, immunoglobulin.

Figure 4. SPE profiles during the autologous stem cell transplant and relapse phases of the immunoglobulin D-κ disease. Serum samples were collected from the patient at the indicated timepoints and SPE was then performed in order to quantify the indicated protein fractions. The tables flanking each SPE panel present the percentage values of the indicated protein fractions. The black arrows depict the monoclonal component observed within the gamma region of the indicated serum SPE profiles and protein fraction tables. ASCT, autologous stem cell transplant; SPE, serum protein electrophoresis.
first ASCT performed in April 2008 (Fig. 2), in addition to evaluation of other classical serological parameters, including β2 M, lactate dehydrogenase, Ca and hemoglobin). FLC/IgD parameters were also evaluated for the whole duration of post-ASCT and disease relapse (Fig. 2 and Table I).

In July 2012, after 4 years of ASCT, the levels of IgD first exhibited a substantial increase above the normal range (Fig. 3 and Table I), and 8 months later, in March 2013, the levels of κ-sFLC exhibited a further significant increase (Fig. 3). Due to this κ-sFLC increase, the presence of an IgD-κ MM was further confirmed by sIFE and urine IFE (Fig. 1B).

Accordingly, in view of a possible relapse, the patient agreed to undergo a bone marrow aspirate in March 2013, evidencing a PC population (4% of bone marrow cells) with the typical phenotypic hallmarks of CD38+ CD138+ CD28+ CD56+ CD117+ CD19 CD45− cells, including the presence of neoplastic PCs with κ light chains restriction, as indicated by the flow cytometric analysis performed at relapse (Fig. 1A). In addition, SPE was performed, which further supported the recurrence of a monoclonal peak inside the γ region. This recurrence was also confirmed by the percentage values of the γ regions from the SPE and IFE profiles (Fig. 4). Indeed, the high γ fraction value depicted in the pre-ASCT phase (10.1%, Fig. 4) reflects the values observed at relapse (18.3%, Fig. 4); there are similarly high values compared with post-ASCT (4.7%, Fig. 4).

Upon another chemotherapy line, the patient underwent a second ASCT, and is currently monitored by measurement of sFLC and total heavy chain IgD.

Discussion

The present study reports the follow-up of a patient with IgD-κ MM that requires a careful approach and monitoring.

The patient refused bone marrow aspirate in various occasions, even under suspicion of relapse; thus, the patient had to be followed up by means of sFLC and total heavy chain IgD measurements for monitoring MRD. The sFLC values over the four BMD cycles were generally constant, indicating the unresponsiveness of the patient. Compared with pre-ASCT levels, the total IgD and light chain values displayed a post-ASCT decrease, including the FLC levels. This was further confirmed by the disappearance of the κ-sFLC in the post-ASCT IFE. In addition, the total heavy chain IgD and κ-sFLC values observed in July 2012 suggested a potential relapse of the disease, since a consequent relapse in March 2013 supported by the relative sIFE values was observed. These findings were also confirmed by the flow cytometric analysis performed at relapse, which demonstrated unbalanced expression levels of κ/λ chains, also displaying the presence of neoplastic PCs. Lastly, the SPE profiles of the patient appeared to be compatible with the overall diagnostic evaluation of the disease evolution, and provided further confirmation to the reliability of this unusual IgD-κ MM patient follow-up.

These data clearly suggest a coherent outcome of heavy chain and FLC levels alongside the diagnostic profile, and demonstrate its effectiveness as an early marker for diagnosis by monitoring the MRD and relapse of IgD-κ MM. Furthermore, in the present and peculiar case study, the availability of a rapid, quantitative and non-invasive test has been revealed of high significance in the monitoring of IgD-κ MM patients, particularly when bone marrow aspirate analysis is not available. In addition, evaluation of serum total heavy chain IgD could represent another useful clinical tool when employed in specialized centers where IgD MM cases could be better characterized and monitored (9,11). Finally, the present conclusions appears to be in line with the recent International Myeloma Working Group statements for MM patients that are not eligible for ASCT (12).

Acknowledgements

The authors are grateful to Dr Gaia Illuminati and Miss Marianna Attanasio (Clinical Pathology Unit, Italian National Cancer Institute ‘Regina Elena’) for their technical support on sample bio-banking and analytical procedures.

References

1. Geng C, Liu N, Yang G, Liu A, Leng Y, Wang H, Li L, Wu Y, Li Y and Chen W: Retrospective analysis of 264 multiple myeloma patients. Oncol Lett 5: 707-713, 2013.
2. Raab MS, Poldar K, Breitkreutz I, Richardson PG and Anderson KC: Multiple myeloma. Lancet 374: 324-339, 2009.
3. Pandey S and Kyle RA: Unusual myelomas: A review of IgD and IgE variants. Oncology (Williston Park) 27: 798-803, 2013.
4. Faiva B, Martinez-Lopez J, Vidriales MB, Mateos MV, Montblan MA, Fernandez-Redondo E, Alonso L, Oriol A, Teruel AL, de Paz R, et al: Comparison of immunofixation, serum free light chain and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol 29: 1627-1633, 2011.
5. Sinclair D: IgD myeloma: Clinical, biological and laboratory features. Clin Lab 48: 617-622, 2002.
6. Richardson PG, Laubach J, Paba-Prada C and Anderson KC: IgD and IgE variants of myeloma: Valuable insights and therapeutic opportunities. Oncology (Williston Park) 27: 803-804, 2013.
7. Ferrero S, Drandi D, Mantoan B, Ghione P, Omede P and Ladetto M: Minimal residual disease detection in lymphoma and multiple myeloma: Impact on therapeutic paradigms. Hematol Oncol 29: 167-176, 2011.
8. Ozaki S, Harada T, Saitoh T, Shimazaki C, Itagaki M, Asaoku H, Kuroda Y, Chou T, Yoshiki Y, Suzuki K, et al: Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the japanese society of myeloma and the european myeloma network. Acta Haematol 132: 211-219, 2014.
9. Pisani F, Petrucci MT, Giannarelli D, Bongarzoni V, Montblan MA, De Stefano V, La Verde G, Gentilini F, Levi A, Za T, et al: IgD multiple myeloma a descriptive report of 17 cases: Survival and response to therapy. J Exp Clin Cancer Res 31: 17, 2012.
10. Fu C, Wang J, Xin X, Liu H, Xue S, Ma X, Jin Z, Sun A, Qiu H and Wu D: Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients. Exp Ther Med 6: 977-982, 2013.
11. Morabito F, Gentile M, Cioll S, Petrucci MT, Galimberti S, Mele G, Casulli AF, Mannina D, Piro E, Pinotti G, et al: Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: A retrospective study of Italian Myeloma Network GIMEMA. Eur J Haematol 84: 223-228, 2010.
12. Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R, Einsele H, Anderson KC, et al: International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 32: 587-600, 2014.